Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,673,925
  • Shares Outstanding, K 192,323
  • Annual Sales, $ 3,221 M
  • Annual Income, $ 348,900 K
  • EBIT $ 429 M
  • EBITDA $ 504 M
  • 60-Month Beta 0.29
  • Price/Sales 3.42
  • Price/Cash Flow 20.06
  • Price/Book 1.81

Options Overview Details

View History
  • Implied Volatility 43.84% (+4.06%)
  • Historical Volatility 27.28%
  • IV Percentile 79%
  • IV Rank 58.06%
  • IV High 55.63% on 04/10/25
  • IV Low 27.50% on 01/15/26
  • Expected Move (DTE 13) 3.03 (5.45%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 667
  • Volume Avg (30-Day) 1,133
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 35,284
  • Open Int (30-Day) 39,094
  • Expected Range 52.47 to 58.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.89
  • Number of Estimates 8
  • High Estimate $1.05
  • Low Estimate $0.60
  • Prior Year $0.98
  • Growth Rate Est. (year over year) -9.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.35 +4.02%
on 03/24/26
61.97 -10.44%
on 03/10/26
-4.24 (-7.10%)
since 03/02/26
3-Month
53.35 +4.02%
on 03/24/26
66.28 -16.26%
on 02/24/26
-3.95 (-6.64%)
since 01/02/26
52-Week
50.76 +9.34%
on 11/07/25
68.54 -19.03%
on 04/03/25
-12.82 (-18.76%)
since 04/02/25

Most Recent Stories

More News
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 19.14 (-3.53%)
BMRN : 55.50 (-3.04%)
REGN : 761.85 (-1.98%)
MRNA : 49.20 (-1.66%)
BIIB : 177.34 (-3.50%)
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky

1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky

BMRN : 55.50 (-3.04%)
MSCI : 544.78 (+1.47%)
FBRT : 8.45 (+0.72%)
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

BMRN : 55.50 (-3.04%)
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building...

BMRN : 55.50 (-3.04%)
2 Mid-Cap Stocks with Exciting Potential and 1 We Question

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

BMRN : 55.50 (-3.04%)
GNRC : 194.09 (-2.49%)
PINS : 18.18 (-0.60%)
2 Reasons to Like BMRN (and 1 Not So Much)

2 Reasons to Like BMRN (and 1 Not So Much)

BMRN : 55.50 (-3.04%)
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study

BMRN : 55.50 (-3.04%)
BioMarin to Participate in Four Upcoming Investor Conferences in March

SAN RAFAEL, Calif. , Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

BMRN : 55.50 (-3.04%)
BioMarin: Q4 Earnings Snapshot

BioMarin: Q4 Earnings Snapshot

BMRN : 55.50 (-3.04%)
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BMRN : 55.50 (-3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 58.53
2nd Resistance Point 57.54
1st Resistance Point 56.52
Last Price 55.50
1st Support Level 54.51
2nd Support Level 53.52
3rd Support Level 52.50

See More

52-Week High 68.54
Fibonacci 61.8% 61.75
Fibonacci 50% 59.65
Fibonacci 38.2% 57.55
Last Price 55.50
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.